European shares rebound as U.S. stimulus overshadows virus worries
Reuters
Published Dec 22, 2020 05:09AM ET
By Susan Mathew and Supriya R
(Reuters) - European shares rose on Tuesday as the approval of a U.S. stimulus package helped allay worries of a further dent to the global economy from a new coronavirus strain in the UK.
The pan-European STOXX 600 index rose 1%, recovering from a more than 2% slide in the previous session, which was also its biggest one-day drop in nearly two months.
The U.S. Congress on Monday approved an $892 billion fiscal stimulus following days of furious negotiation. President Donald trump is expected to sign it into law, keeping hopes of an economic recovery alive.
Strict lockdowns went into effect in Britain on Monday to curb the spread of the new coronavirus strain said to be up to 70% more transmissible than the original, triggering border bans and travel restrictions from several countries.
The BBC reported that Britain and France would announce a deal to restart freight by Wednesday.
Record growth in UK GDP, however, saw London's blue-chip index reverse early losses to trade 0.3% higher, held back only by materials and energy stocks, which tracked declining prices of underlying commodities. [O/R][MET/L][.L]
"The GDP reading ... has shielded the markets slightly," said Connor Campbell, a financial analyst at Spreadex.
"You've still got the COVID travel ban. That is really weighing on the UK markets and preventing them from doing much this morning. I think perhaps they could have been lower if that GDP figure hadn't been revised higher."
Banks led the rebound in Europe, followed by retailers and tech stocks.
U.S. stocks cut losses overnight on stimulus news and, while Dow Jones futures traded flat, S&P and Nasdaq futures pointed to a higher open, signalling European shares could hold on to their gains on cautiously upbeat sentiment. (N)
AstraZeneca (NASDAQ:AZN) lost 1.4% after its experimental asthma drug developed with U.S partner Amgen (NASDAQ:AMGN) failed to meet the main goal of a late-stage trial.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.